Research output per year
Research output per year
Search results
-
2024
Neurocognitive insights: functional magnetic resonance imaging of spatial working memory and sustained attention in people with systemic lupus erythematous
Barraclough, M., McCowen, M., McKie, S., Kafkas, A., Parker, B., Diaz-Martinez, J., Knight, A., Bingham, K., Li, M., Su, J., Kakvan, M., Grajales, C., Tartaglia, M., Ruttan, L., Wither, J., Bonilla, D., Anderson, N., Montaldi, D., Elliott, R. & Katz, P. & 4 others, , 24 Apr 2024, In: Rheumatology. 63, 1 p., keae163196.Research output: Contribution to journal › Meeting Abstract › peer-review
-
2019
SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)
Nathan, P., Needham, A., Corrie, P. G., Danson, S., Evans, J., Ochsenreither, S., Kumar, S., Goodman, A., Larkin, J. M. G., Karydis, I., Steven, N. M., Lorigan, P., Plummer, R., Patel, P., Shaw, H. M., Leyvraz, S., Rawcliffe, C., Psarelli, E. E., Handley, L. & Sacco, J. J., Oct 2019, In: Annals of Oncology. 30Research output: Contribution to journal › Meeting Abstract › peer-review
-
2009
Plitidepsin alone or with dacarbazine (DTIC) as first-line treatment for advanced unresectable melanoma (AUM) [JCO Abstract 9059]
Plummer, R., Hayward, L., Lorigan, P., Soriano, V., Moiseyenko, V., Szyldergemajn, S., Prados, R., Smyth, J. & Calvert, H., 2009, In: Journal of Clinical Oncology. 27, 15, p. 9059Research output: Contribution to journal › Meeting Abstract › peer-review
-
2006
First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM)
Plummer, R., Lorigan, P., Evans, J., Steven, N., Middleton, M., Wilson, R., Snow, K., Dewji, R. & Calvert, H., 20 Jun 2006, In: Journal of Clinical Oncology. 24, 18, p. 456S-456S 1 p.Research output: Contribution to journal › Meeting Abstract › peer-review